市场调查报告书
商品编码
1471252
微载体市场:按产品、应用和最终用户划分 - 2024-2030 年全球预测Microcarriers Market by Product (Consumables, Equipment), Application (Biologics Manufacturing, Cell Therapy, Vaccine Manufacturing), End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年微载体市场规模为21.6亿美元,2024年将达23.7亿美元,2030年将达42.2亿美元,复合年增长率为9.99%。
微载体是由聚葡萄糖、聚苯乙烯、明胶和玻璃等材料製成的小球形珠子,为贴壁依赖性细胞附着和生长提供表面。这些颗粒的尺寸范围为 100 至 300 μm,可用于反应器和其他细胞培养系统,以提高细胞生产过程的扩充性和效率。微载体的主要目的是促进需要基材进行黏附和增殖的贴壁依赖性细胞的大规模增殖。在生物技术中,微载体对于生产治疗性蛋白质、疫苗和基于细胞的治疗方法(例如干细胞和免疫细胞)至关重要。微载体具有较高的表面积与体积比,与平面上传统的二维 (2D) 单层培养相比,可以更有效地利用反应器内的培养基和空间。考虑到干细胞在再生医学、组织工程和药物发现的潜力,对更有效的培养系统的需求日益增长。微载体已成为大规模扩增多功能细胞(PSC)的关键要素。 PSC 可以分化成多种细胞类型,提供商业性製造所需的可扩展性和稳健性。此外,免疫疗法也取得了显着进展,嵌合嵌合体受体(CAR)T细胞疗法等过继性细胞转移疗法在癌症治疗中显示出显着的临床疗效。与这些治疗相关的挑战之一是无法为治疗应用提供足够数量的高品质免疫细胞。然而,随着新的细胞治疗方法不断出现并走向实用化,微载体技术预计仍将是其成功製造的关键要素。
主要市场统计 | |
---|---|
基准年[2023] | 21.6亿美元 |
预测年份 [2024] | 23.7亿美元 |
预测年份 [2030] | 42.2亿美元 |
复合年增长率(%) | 9.99% |
基于微载体的设备创新,提高产品可扩展性和生产製程弹性
在微载体技术中,产品分为消耗品和设备。消耗品直接影响细胞生长和维持,包括微载体、培养基、血清、缓衝液/试剂和抛弃式。另一方面,反应器、细胞成像系统/细胞计数器和离心/过滤装置等设备对于使用微载体的细胞培养系统的有效运作至关重要。研究人员优先考虑高品质的产品,以确保最佳的细胞生长,同时保持无菌。因此,由于污染风险降低且易于扩展,因此优选无血清培养基、化学成分确定的培养基和一次性反应器。
应用微载体在生物医学应用的广泛使用,在组织工程和再生医学的潜在应用
微载体在生物技术、製药和再生医学领域的各种应用中发挥着重要作用。它支持大规模细胞培养、提高疫苗生产效率、实现组织工程方法、促进药物发现活动以及促进基因治疗进步的能力使其在现代生命科学研究和开发中发挥重要作用。在生技药品製造中,微载体促进贴壁细胞的生长,以製造蛋白质和单株抗体等大分子。微载体支持间质干细胞(MSC) 和嵌合体抗原受体 T 细胞 (CAR-T) 等治疗细胞的规模化生产。微载体显示出组织工程应用的潜力,因为它们能够支援类似于天然组织架构的3D 环境。 CAR-T细胞透过允许多种细胞类型的空间组织、促进细胞间通讯并支持细胞外基质沉积,为创建功能性组织提供了绝佳的平台。在再生医学中,基于微载体的系统可用于扩增干细胞,以产生足够的细胞用于针对器官修復或替代的治疗。在疫苗生产中,微载体能够使贴壁细胞生长,产生疫苗配方所需的病毒载体和抗原。整体而言,每种应用都需要具有独特特性的客製化微载体解决方案,以满足不同的要求。透过专注于在生技药品製造中生产高品质蛋白质、推进细胞治疗中的再生医学以及应对疫苗製造中的全球公共卫生挑战,製造商正在提高这些关键救生技术的效率,并不断创新以改进我们的技术。
最终用户:医疗机构中微载体的使用重点在于其性能的准确性和扩充性。
参与细胞培养和疫苗製造的委外研发机构(CRO) 和研究机构依靠创新、高效的生物製程技术来进行研究、药物发现和临床前测试。 CRO 特别受益于支持细胞培养规模扩大的微载体,这对于高通量筛检和优化治疗药物生产至关重要。在研究实验室中,微载体用于促进贴壁依赖性细胞增殖,这对于研究细胞行为和开发组织工程应用非常重要。同时,製药和生物技术公司主要利用微载体技术生产疫苗、治疗性蛋白质和再生药物。製药业对效率和成本效益的追求需要能够适应大型生产设施并与自动化系统无缝整合的微载体。
区域洞察
美洲、欧洲、亚太地区和中东非洲不断成长的市场证明了对微载体的高需求。以美国为代表的美洲地区拥有先进的生物技术基础设施和政府对研究活动的大力支持。欧盟 (EU) 优先资助与医疗保健相关的研究倡议,从而导致基于微载体的细胞治疗技术的需求增加和进步。在中东和非洲,医疗基础设施的改善和政府投资激发了人们对微载体应用的兴趣。亚太地区,特别是中国和日本的成长是由政府主导推动的,包括新材料的专利申请和高品质微载体的表面改性。此外,印度快速扩张的製药业刺激了对利用微载体的更先进细胞培养技术的需求。随着全球对细胞疗法的需求持续成长,对微载体等高效生产系统的需求也日益增长。这些为高效微载体系统的开发和部署以及不同地区相关人员之间的新合作创造了重要的创新机会。
FPNV定位矩阵
FPNV定位矩阵对于评估微载体市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对微载体市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争力评估及资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1. 微载体市场的市场规模与预测为何?
2.在微载体市场的预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3.微载体市场的技术趋势与法规结构是什么?
4.微载体市场主要厂商的市场占有率为何?
5. 进入微载体市场的合适型态和策略手段是什么?
[183 Pages Report] The Microcarriers Market size was estimated at USD 2.16 billion in 2023 and expected to reach USD 2.37 billion in 2024, at a CAGR 9.99% to reach USD 4.22 billion by 2030.
Microcarriers are small spherical beads made from materials such as dextran, polystyrene, gelatin, or glass that provide a surface for anchorage-dependent cells to adhere and grow. These particles range in size from 100 to 300 micrometers and can be used in bioreactors or other cell culture systems to enhance the scalability and efficiency of cell production processes. The primary purpose of microcarriers is to facilitate the large-scale expansion of anchorage-dependent cells that require a substrate for attachment and growth. In biotechnology, microcarriers are essential for producing therapeutic proteins, vaccines, and cell-based therapies, such as stem cells or immune cells. Microcarriers provide a high surface-to-volume ratio, allowing more efficient use of culture medium and space in bioreactors than traditional two-dimensional (2D) monolayer cultures on flat surfaces. There has been an increasing need for more efficient systems for the cultivation of stem cells, given their potential in regenerative medicine, tissue engineering, and drug discovery. Microcarriers have emerged as a key component in the large-scale expansion of pluripotent stem cells (PSCs), which can differentiate into numerous cell types and provide the scalability and robustness required for commercial manufacturing. Moreover, immunotherapy has grown tremendously, with adoptive cell transfer treatments such as chimeric antigen receptor (CAR) T-cell therapy demonstrating significant clinical results in cancer treatment. One of the challenges associated with these therapies is the inability to provide sufficient quantities of high-quality immune cells for therapeutic application. However, as new cell-based therapies continue to emerge and advance toward commercialization, microcarrier technology is expected to remain a critical component driving their manufacturing success.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.16 billion |
Estimated Year [2024] | USD 2.37 billion |
Forecast Year [2030] | USD 4.22 billion |
CAGR (%) | 9.99% |
Product: Innovations in the microcarrier-based equipment for increasing scalability and production process flexibility
In microcarrier technology, products are categorized into consumables and equipment. Consumables, which directly impact cell growth and maintenance, consist of microcarriers, media, sera, buffers/reagents, and disposables. On the other hand, equipment is crucial for efficient microcarrier-based cell culture systems operation which includes bioreactors, cell imaging systems/cell counters, and centrifugation/filtration devices. Researchers prioritize high-quality products ensuring optimal cell growth while maintaining sterility. Consequently, serum-free or chemically-defined media and disposable bioreactors gain preference due to reduced contamination risks and scalability ease.
Application: Extensive usage of microcarriers in biomedical applications, with potential applications in tissue engineering and regenerative medicine
Microcarriers play a crucial role in various applications across biotechnology, pharmaceuticals, and regenerative medicine sectors. Their ability to support large-scale cell cultivation, improve vaccine production efficiency, enable tissue engineering approaches, facilitate drug discovery efforts, and contribute to gene therapy advancements highlights their significance in modern life science research and development. In biologics manufacturing, microcarriers facilitate the growth of adherent cells for producing large molecules, such as proteins and monoclonal antibodies. Microcarriers support scalable production of therapeutic cells, including mesenchymal stem cells (MSCs) and chimeric antigen receptor T-cells (CAR-T). Microcarriers have shown potential in tissue engineering applications due to their ability to support a 3D environment resembling native tissues' architecture. They offer an excellent platform for generating functional tissues by enabling the spatial organization of multiple cell types, promoting cell-cell communication, and supporting extracellular matrix deposition. In regenerative medicine, microcarrier-based systems can be employed in stem cell expansion to produce sufficient cells required for therapies targeting organ repair or replacement. For vaccine manufacturing, microcarriers enable the expansion of adherent cells responsible for producing viral vectors or antigens necessary for vaccine formulation. Overall, each application demands tailored microcarrier solutions with unique properties to address diverse requirements. Manufacturers continuously innovate to improve the efficiency of these crucial life-saving technologies by catering to biologics manufacturing's focus on high-quality protein production; cell therapy's emphasis on regenerative medicine advancements; and vaccine manufacturing's response to global public health challenges.
End User: Utilization of microcarriers in healthcare institutions in preference to their performance accuracy and scalability
Contract research organizations (CROs) and research institutes involved in cell culture and vaccine production rely on innovative and efficient bioprocessing technologies to conduct research, drug discovery, and preclinical trials. CROs particularly benefit from microcarriers as they support the scale-up of cell cultures, which is essential for high-throughput screening and optimizing therapeutic production. Research institutes use microcarriers to facilitate the growth of anchorage-dependent cells, which is important for studying cell behavior and developing tissue engineering applications. On the other hand, pharmaceutical and biotechnology companies leverage microcarrier technology primarily to produce vaccines, therapeutic proteins, and regenerative medicines. The pharmaceutical industry, aiming for efficiency and cost-effectiveness, demands microcarriers compatible with large-scale production facilities and can integrate seamlessly with automated systems.
Regional Insights
Microcarriers are in high demand, as evidenced by their increasing market growth in the Americas, Europe, the Asia-Pacific, and the Middle East and Africa regions. The Americas region, led by the United States, boasts advanced biotechnology infrastructure and strong government support for research activities. The European Union prioritizes funding for healthcare-related research initiatives, resulting in increased demand and advancements in cell therapy technologies that utilize microcarriers. In the Middle East and Africa, improved healthcare infrastructure and government investments have sparked interest in the application of microcarriers. The Asia-Pacific region, particularly China and Japan, is experiencing growth driven by government initiatives, including patent filings for novel materials and surface modifications for high-quality microcarriers. Additionally, India's rapidly expanding pharmaceutical sector is stimulating the need for more advanced cell culture technologies that utilize microcarriers. As the global demand for cell-based therapies continues to rise, there is an increasing need for efficient production systems such as microcarriers. These create significant opportunities for innovation in the development and implementation of efficient microcarrier-based systems and new collaboration among stakeholders in various regions.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Microcarriers Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Microcarriers Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Microcarriers Market, highlighting leading vendors and their innovative profiles. These include Aber Instruments Ltd., Bangs Laboratories, Inc., Bio-Rad Laboratories, Inc., Carroucell, ChemoMetec A/S, Cole-Parmer Instrument Company, Corning Inc., Cytiva, denovoMATRIX GmbH, Entegris, Inc., Eppendorf AG, Esco Vaccixcell, FUJIFILM Holdings Corporation, Getinge AB, Irvine Scientific, Kuraray Co., Ltd., Lonza Group AG, Matrix F.T., Merck KGaA, Modern Meadow Inc., nanoComposix, Inc., Pall Corporation, Polysciences Inc., PromoCell GmbH, Repligen Corporation, RoosterBio, Inc., Sartorius AG, Sunresin New Materials Co.Ltd., Teijin Limited, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Microcarriers Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Microcarriers Market?
3. What are the technology trends and regulatory frameworks in the Microcarriers Market?
4. What is the market share of the leading vendors in the Microcarriers Market?
5. Which modes and strategic moves are suitable for entering the Microcarriers Market?